623 related articles for article (PubMed ID: 35320468)
21. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).
Bewersdorf JP; Zeidan AM
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807279
[TBL] [Abstract][Full Text] [Related]
22. Treatment of low-risk myelodysplastic syndromes.
Santini V
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):462-469. PubMed ID: 27913517
[TBL] [Abstract][Full Text] [Related]
23. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Garcia-Manero G; Fenaux P
J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
[TBL] [Abstract][Full Text] [Related]
24. Evolving therapies for lower-risk myelodysplastic syndromes.
Bewersdorf JP; Zeidan AM
Ann Hematol; 2020 Apr; 99(4):677-692. PubMed ID: 32078008
[TBL] [Abstract][Full Text] [Related]
25. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA; Taylor J
JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
28. Next-generation therapy for lower-risk MDS.
Sébert M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):59-64. PubMed ID: 38066862
[TBL] [Abstract][Full Text] [Related]
29. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
30. Clinical decision-making and treatment of myelodysplastic syndromes.
Hellström-Lindberg ES; Kröger N
Blood; 2023 Dec; 142(26):2268-2281. PubMed ID: 37874917
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Stahl M; Zeidan AM
Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
[TBL] [Abstract][Full Text] [Related]
32. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
33. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
[TBL] [Abstract][Full Text] [Related]
34. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.
Garcia-Manero G; Almeida A; Giagounidis A; Platzbecker U; Garcia R; Voso MT; Larsen SR; Valcarcel D; Silverman LR; Skikne B; Santini V
BMC Hematol; 2016; 16():12. PubMed ID: 27148452
[TBL] [Abstract][Full Text] [Related]
35. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
36. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
Hatoum HT; Lin SJ; Buchner D; Kim E
Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
[TBL] [Abstract][Full Text] [Related]
37. Improving Treatment for Myelodysplastic Syndromes Patients.
Montoro J; Yerlikaya A; Ali A; Raza A
Curr Treat Options Oncol; 2018 Oct; 19(12):66. PubMed ID: 30362079
[TBL] [Abstract][Full Text] [Related]
38. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
39. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
[TBL] [Abstract][Full Text] [Related]
40. Current and emerging strategies for management of myelodysplastic syndromes.
Saygin C; Carraway HE
Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]